Efficacy of Tocilizumab on Patients With COVID-19
Study Details
Study Description
Brief Summary
This is a randomized, double blind, multi-center study to evaluate the effects of tocilizumab compared to placebo on patient outcomes in participants with confirmed SARS-CoV-2 infection and evidence of systemic inflammation.
The aim of this study is to test the effect of Tocilizumab on multi-organ dysfunction in a phase 3 randomized controlled trial among hospitalized patients with COVID-19 infection.
Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures. Multi-organ dysfunction will be measured as the incidence of the following composite endpoint (mechanical ventilation, renal replacement therapy, mechanical support, need for inotropes or vasopressors, liver dysfunction (increased bilirubin), and all-cause mortality). We will also assess multiple pre-specified secondary (exploratory) endpoints and safety endpoints.
We hypothesize that, as compared to placebo, tocilizumab will reduce transfer to the ICU, need for mechanical ventilation, increase rates of hospital discharge in patients diagnosed with severe COVID-19 infection and evidence of exaggerated inflammatory response.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
As of April 3, 2020, COVID-19 has been confirmed in over 1 million people worldwide, with an estimated symptomatic case fatality ratio of around 1.4%. Currently without an effective treatment for SARS-CoV-2 there is an urgent need for effective treatment to curtail the rate of respiratory failure, the leading cause of mortality in COVID-19 disease. Moreover, with increasing numbers of patients requiring intensive unit level care and mechanical ventilation, nations are already having to triage patients for ventilatory support due to limited resources and healthcare systems around the world being stretched to the point of collapse, highlighting the importance of identifying interventions that could prevent the development of respiratory failure for these patients.
The disease course of COVID-19 includes an incubation period, an acute viral phase that most commonly presents with flu-like symptoms that in some individuals progresses to a severe hyperinflammatory phase marked by acute respiratory distress syndrome (ARDS) and hypoxemic respiratory failure.Though there is spectrum of clinical course, many progress to the hyperinflammatory phase around day seven of symptoms, often requiring intensive care unit (ICU) level care and mechanical ventilation. Accumulating evidence suggests that the pathophysiology underlying this profound decline is a severe inflammatory response as demonstrated by multi organ system dysfunction akin to cytokine release syndrome (CRS)/macrophage activation syndrome (MAS).CRS/MAS is a systemic hyperinflammatory syndrome on a spectrum with secondary hemophagocytic lymphohistiocytosis (sHLH), typically characterized by multiorgan failure that is often triggered by viral infections in the setting of excessive immune activation, typically with marked hyperferritinemia.Postmortem assessment of patients with COVID-19 have demonstrated pathologic findings consistent with MAS such as mono/lymphocytic infiltrates within the lung parenchyma with associated edema and alveolar congestion, splenic necrosis with macrophage proliferation and hemophagocytosis, as well as a lymphocyte/histiocyte predominate infiltrate of portal vasculature accompanying liver necrosis and sinusoidal congestion.Cytokine profiling of patients with MAS/sHLH overlaps with that seen in patients with severe COVID-19 and includes elevated levels of IL-1, IL-2, IL-7, IL-6, G-CSF, MCP- 1, and TNF-α as well as elevated D-dimer, C-reactive protein, LDH and troponins.Moreover, preliminary data from a non-randomized series of COVID-19 patients with "severe or critical COVID-19" from China who were treated with tocilizumab (in addition to standard therapies) showed they had dramatic improvement in fever, arterial oxygen saturation and inflammatory markers within the first 24-hours following administration.
Taken together, these data strongly suggest an immunologic link between COVID-19 and immune dysregulation resulting in MAS. Clinical trials are already underway studying the role of immunomodulatory therapy including modulation of IL-1 and IL-6 and downstream pathways in the setting of CAR-T induced MAS (NCT04150913, NCT04071366) and agents such anakinra and tocilizumab have been used in this context with promising results and good safety profiles. There is an urgent and dire need to study the therapeutic role for immunomodulatory therapy in COVID-19 disease to both halt disease progression in patients at an individual level and prevent the inevitable saturation of healthcare resources at a systems level, to which end there are numerous ongoing international trials to expand these efforts into the setting of COVID-19 infection (ChiCTR2000029765, NCT04324021, TOCOVID-19). Based on the MGH experience thus far with COVID-19, including over 200 patients to date, the need for mechanical ventilation has been approximately 30%. With the upcoming surge anticipated between April 17th and 21st we expect the need for hundreds of additional ICU beds. Investigators propose a trial of IL-6 receptor blockade with tocilizumab given early in disease course to try to prevent progression of COVID-19.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Tocilizumab Review effect of Tocilizumab on multi-organ dysfunction in a phase 3 randomized controlled trial among hospitalized patients with COVID-19 infection. Participants will receive an intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg) tocilizumab.Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures. |
Drug: Tocilizumab
Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:
Tocilizumab 8mg x 1 (n=185)
Standard of care/Placebo (n=93)
Other Names:
|
| Placebo Comparator: Standard of care plus placebo Participants will receive an placebo intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg).Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures. |
Drug: Placebos
Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:
Tocilizumab 8mg x 1 (n=185)
Standard of care/Placebo (n=93)
|
Outcome Measures
Primary Outcome Measures
- Mechanical Ventilation or Death [28 days]
Time from administration of the investigational agent (or placebo) to requiring mechanical ventilation and intubation, or death for subjects who die prior to intubation. The percentages of patients who have been intubated or died as of day 14 and day 28 are estimated from the Kaplan-Meier curve.
Secondary Outcome Measures
- Clinical Worsening on Ordinal Scale [28 days]
Time from administration of the investigational medication (or placebo) to at least one point worsening on the clinical improvement scale for subjects requiring supplemental oxygen (score >= 3) at baseline, or at least two point worsening otherwise (score = 2 at baseline). The percentages of patients who have worsened as of day 14 and day 28 are estimated from the Kaplan-Meier curve. Ordinal Scale Discharged Non-ICU hospital ward not requiring supplemental oxygen Non-ICU hospital ward requiring supplemental oxygen ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen ICU, requiring intubation and mechanical ventilation ICU, requiring ECMO or mechanical ventilation and additional organ support Death
- Discontinuation of Supplemental Oxygen Among Patients Receiving it at Baseline [28 days]
Time from administration of the investigational agent (or placebo) to absence of the need for supplemental oxygen among those who require at least supplemental oxygen at baseline. The percentages of patients who have discontinued supplemental oxygen as of day 14 and day 28 are estimated from the Kaplan-Meier curve.
Other Outcome Measures
- Duration of Supplemental Oxygen [28 days]
Time from initiation of supplemental oxygen to end of supplemental oxygen use during 28-day study follow-up period. We includes all subjects in the analysis by assigning all subjects who did not receive supplemental oxygen a value of 0. Subjects who died prior to discontinuation of supplemental oxygen were given a value of the number of days from when supplemental oxygen began until the end of the follow-up period.
- Duration of Mechanical Ventilation [28 days]
Time from initiation of mechanical ventilation to end of mechanical ventilation during 28-day study follow-up period, among patients who received mechanical ventilation. Event times of patients who died without discontinuation of mechanical ventilation were censored at 28 days. Median and inter-quartile range (IQR) were estimated using Kaplan-Meier curves. The upper limit for the IQR was not reached for both arms and entered as 28 in the outcome measure data table.
- Mortality [28 days]
Time from administration of the investigational agent (or placebo) to death. The percentage of patients who have died as of day 14 and day 28 are estimated from the Kaplan-Meier curve.
- ICU Admission or Death Among Those Not in the ICU at the Time of Administration of Investigational Agent (or Placebo) [28 days]
The percentage of subjects requiring ICU admission between baseline and 28 days is calculated by dividing the number of subjects requiring ICU admission over their hospitalization by the number of evaluable subjects (i.e., the number of subjects not in the ICU at the time of investigational treatment administration).
- Hospital Discharge [28 days]
Time from administration of the investigational medication (or placebo) to initial hospital discharge. Event times for patient who die are censored at day 29 to indicate that they never left the hospital during the follow-up period. The percentages of patients who were discharged as of day 14 and day 28 are estimated from the Kaplan-Meier curve.
- Clinical Improvement on Ordinal Scale [28 days]
Time to first improvement from administration of the investigational agent (or placebo) of at least 2 points (or the maximum amount) on the ordinal scale. Event times for patients who died prior to reaching this endpoint are censored at 29 days. Ordinal Scale Discharged Non-ICU hospital ward not requiring supplemental oxygen Non-ICU hospital ward requiring supplemental oxygen ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen ICU, requiring intubation and mechanical ventilation ICU, requiring ECMO or mechanical ventilation and additional organ support Death
Eligibility Criteria
Criteria
Inclusion criteria:
Subjects who meet all of the following criteria will be eligible to participate in the study:
-
Must have provided informed consent in a manner approved by the Investigator's Institutional Review Board (IRB) or Independent Ethics Committee (IEC) prior to any assessments. If a patient is unable to provide informed consent due to their medical condition, the patient's legally authorized representative may consent on behalf of the study patient, as permitted by local law and institutional Standard Operating Procedures;
-
Age Range: 19-85 years old
-
Male or female gender
-
Confirmed SARS-CoV-2 infection by nasopharyngeal swab PCR or serum assay for IgM antibody
-
Requiring hospital but not mechanical ventilation
-
Oxygen supplementation not greater than 10L delivered by any device
-
WITH evidence of severe COVID-19 (at least 2 of the following):
-
Fever > 38C within 72 hours
-
Pulmonary infiltrate on CXR
-
Need for supplemental O2 to maintain saturation > 92%
-
AND at least 1 of the following:
-
Ferritin > 500 ng/ml
-
CRP > 50 mg/L
-
LDH >250 U/L
-
D-dimer > 1000 ng/mL
-
Women of childbearing potential (ie, not post-menopausal or surgically sterilized) must have a negative highly sensitive urine or serum pregnancy test before randomization. Participating women of childbearing potential must be willing to consistently use effective methods of contraception (ie, condom, combined oral contraceptive, implant, injectable, indwelling intrauterine device, or a vasectomized partner) from screening until at least 90 days after administration of the last dose of study drug;
-
The subject must be willing and able to provide informed consent and abide all study requirements and restrictions.
Exclusion criteria:
Subjects who meet any of the following criteria will be excluded from participation in the study:
-
Unable to provide verbal informed consent or have verbal agreement to participate through attestation and signature of a Witness required, as outlined in the Partners IRB's Table for Consenting in COVID Research that is More than Minimal Risk.
-
Subjects between the ages of 79 and 86 will be excluded if they have NYHA Class III/IV heart failure, insulin-dependent diabetes mellitus, angina, or treatment of a malignancy (excluding non-melanoma skin cancer) within six months
-
Uncontrolled bacterial, fungal, or non-COVID viral infection
-
Active TB
-
Any prior investigational immunosuppressive therapy within 28-days or 3 half-lives of the agent (for instance with biologic or JAK inhibitor)
-
Any concurrent immunosuppressive medication that the PI believes would put the patient at higher risk
-
Receipt of intravenous tocilizumab for the treatment of a non-COVID condition within three weeks of the first COVID symptom
-
History of hypersensitivity to tocilizumab
-
Any concurrent immunosuppressive medication that the PI believes would put the patient at higher risk
-
Treatment with other biologic or small-molecule immunosuppressive therapy such as IL1R-antagonism, JAK inhibition, or other agents
-
Treatment with convalescent plasma
-
History of diverticulitis or bowel perforation
-
ANC <500, Platelets <50,000*
-
AST/ALT > 5X ULN
-
Women who are pregnant or planning to get pregnant in the next 90 days;
-
Any condition that could interfere with, or for Known allergy to the study drug or any of its ingredients or known allergy to any other anti IL 6 agents;
-
Any condition that could interfere with or for which the treatment might interfere with, the conduct of the study or interpretation of the study results, or that would, in the opinion of the Investigator, increase the risk of the subject by participating in the study.
We note that anti-viral therapies may be administered to subjects if given in the context of a clinical trial. Nitric oxide treatment is also permitted at the discretion of the care team, ideally in the context of a clinical trial. Co-treatment chloroquine, hydroxychloroquine, and/or azithromycin is permitted for subjects in this protocol.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Massachusetts General Hospital | Boston | Massachusetts | United States | 02114 |
| 2 | Brigham and Women's Hospital | Boston | Massachusetts | United States | 02115 |
| 3 | Newton-Wellesley Hospital | Newton | Massachusetts | United States | 02462 |
Sponsors and Collaborators
- Massachusetts General Hospital
- Genentech, Inc.
Investigators
- Principal Investigator: John H Stone, MD, Massachusetts General Hospital
Study Documents (Full-Text)
More Information
Publications
None provided.- 2020P001159
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Tocilizumab | Placebo |
|---|---|---|
| Arm/Group Description | Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg) | Standard care plus placebo |
| Period Title: Randomization (Safety Population) | ||
| STARTED | 161 | 82 |
| COMPLETED | 161 | 82 |
| NOT COMPLETED | 0 | 0 |
| Period Title: Randomization (Safety Population) | ||
| STARTED | 161 | 82 |
| COMPLETED | 161 | 81 |
| NOT COMPLETED | 0 | 1 |
Baseline Characteristics
| Arm/Group Title | Tocilizumab | Standard of Care Plus Placebo | Total |
|---|---|---|---|
| Arm/Group Description | Review effect of Tocilizumab on multi-organ dysfunction in a phase 3 randomized controlled trial among hospitalized patients with COVID-19 infection. Participants will receive an intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg) tocilizumab. Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures. Tocilizumab: Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms: Tocilizumab 8mg x 1 Standard of care/Placebo | Participants will receive an placebo intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg).Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures. Placebos: Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms: Tocilizumab 8mg x 1 Standard of care/Placebo | Total of all reporting groups |
| Overall Participants | 161 | 82 | 243 |
| Age (years) [Median (Inter-Quartile Range) ] | |||
| Median (Inter-Quartile Range) [years] |
61.6
|
56.5
|
59.8
|
| Sex: Female, Male (Count of Participants) | |||
| Female |
65
40.4%
|
37
45.1%
|
102
42%
|
| Male |
96
59.6%
|
45
54.9%
|
141
58%
|
| Ethnicity (NIH/OMB) (Count of Participants) | |||
| Hispanic or Latino |
70
43.5%
|
39
47.6%
|
109
44.9%
|
| Not Hispanic or Latino |
84
52.2%
|
35
42.7%
|
119
49%
|
| Unknown or Not Reported |
7
4.3%
|
8
9.8%
|
15
6.2%
|
| Race/Ethnicity, Customized (Count of Participants) | |||
| American Indian or Alaska Native |
1
0.6%
|
0
0%
|
1
0.4%
|
| Asian |
7
4.3%
|
2
2.4%
|
9
3.7%
|
| Black |
24
14.9%
|
16
19.5%
|
40
16.5%
|
| Native Hawaiian or Pacific Islander |
0
0%
|
1
1.2%
|
1
0.4%
|
| White |
71
44.1%
|
33
40.2%
|
104
42.8%
|
| Other |
35
21.7%
|
15
18.3%
|
50
20.6%
|
| Unknown |
23
14.3%
|
15
18.3%
|
38
15.6%
|
| Region of Enrollment (Count of Participants) | |||
| United States |
161
100%
|
82
100%
|
243
100%
|
| BMI (kg/m^2) [Median (Inter-Quartile Range) ] | |||
| Median (Inter-Quartile Range) [kg/m^2] |
29.9
|
30.2
|
30.1
|
| BMI ≥ 30 kg/m^2 (Count of Participants) | |||
| Count of Participants [Participants] |
80
49.7%
|
42
51.2%
|
122
50.2%
|
| Days from symptom onset to randomization (days) [Median (Inter-Quartile Range) ] | |||
| Median (Inter-Quartile Range) [days] |
9.0
|
10.0
|
9.0
|
| Hypertension (Count of Participants) | |||
| Count of Participants [Participants] |
80
49.7%
|
38
46.3%
|
118
48.6%
|
| Heart failure (Count of Participants) | |||
| Count of Participants [Participants] |
17
10.6%
|
7
8.5%
|
24
9.9%
|
| History of myocardial infarction (Count of Participants) | |||
| Count of Participants [Participants] |
15
9.3%
|
6
7.3%
|
21
8.6%
|
| Chronic obstructive pulmonary disorder (Count of Participants) | |||
| Count of Participants [Participants] |
15
9.3%
|
7
8.5%
|
22
9.1%
|
| Asthma (Count of Participants) | |||
| Count of Participants [Participants] |
15
9.3%
|
7
8.5%
|
22
9.1%
|
| Smoking status (Count of Participants) | |||
| Current smoker |
7
4.3%
|
0
0%
|
7
2.9%
|
| Former smoker |
46
28.6%
|
26
31.7%
|
72
29.6%
|
| Lifelong nonsmoker |
99
61.5%
|
48
58.5%
|
147
60.5%
|
| Unknown |
9
5.6%
|
8
9.8%
|
17
7%
|
| Diabetes (Count of Participants) | |||
| Count of Participants [Participants] |
45
28%
|
30
36.6%
|
75
30.9%
|
| History of cancer (Count of Participants) | |||
| Count of Participants [Participants] |
22
13.7%
|
8
9.8%
|
30
12.3%
|
Outcome Measures
| Title | Mechanical Ventilation or Death |
|---|---|
| Description | Time from administration of the investigational agent (or placebo) to requiring mechanical ventilation and intubation, or death for subjects who die prior to intubation. The percentages of patients who have been intubated or died as of day 14 and day 28 are estimated from the Kaplan-Meier curve. |
| Time Frame | 28 days |
Outcome Measure Data
| Analysis Population Description |
|---|
| Modified intention-to-treat (mITT) population, which includes 242 patients (161 in the tocilizumab group and 81 in the placebo group) who underwent randomization and received either tocilizumab or placebo before intubation or death |
| Arm/Group Title | Tocilizumab | Placebo |
|---|---|---|
| Arm/Group Description | Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg) | Standard care plus placebo |
| Measure Participants | 161 | 81 |
| 14 days |
9.9
|
10.0
|
| 28 days |
10.6
|
12.5
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Tocilizumab, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.64 |
| Comments | ||
| Method | Log Rank | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
| Estimated Value | 0.83 | |
| Confidence Interval |
(2-Sided) 95% 0.38 to 1.81 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Clinical Worsening on Ordinal Scale |
|---|---|
| Description | Time from administration of the investigational medication (or placebo) to at least one point worsening on the clinical improvement scale for subjects requiring supplemental oxygen (score >= 3) at baseline, or at least two point worsening otherwise (score = 2 at baseline). The percentages of patients who have worsened as of day 14 and day 28 are estimated from the Kaplan-Meier curve. Ordinal Scale Discharged Non-ICU hospital ward not requiring supplemental oxygen Non-ICU hospital ward requiring supplemental oxygen ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen ICU, requiring intubation and mechanical ventilation ICU, requiring ECMO or mechanical ventilation and additional organ support Death |
| Time Frame | 28 days |
Outcome Measure Data
| Analysis Population Description |
|---|
| Modified intention-to-treat (mITT) population, which includes 242 patients (161 in the tocilizumab group and 81 in the placebo group) who underwent randomization and received either tocilizumab or placebo before intubation or death |
| Arm/Group Title | Tocilizumab | Placebo |
|---|---|---|
| Arm/Group Description | Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg) | Standard care plus placebo |
| Measure Participants | 161 | 81 |
| Day 14 |
18.0
|
14.9
|
| Day 28 |
19.3
|
17.4
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Tocilizumab, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.73 |
| Comments | ||
| Method | Log Rank | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
| Estimated Value | 1.11 | |
| Confidence Interval |
(2-Sided) 95% 0.59 to 2.10 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Discontinuation of Supplemental Oxygen Among Patients Receiving it at Baseline |
|---|---|
| Description | Time from administration of the investigational agent (or placebo) to absence of the need for supplemental oxygen among those who require at least supplemental oxygen at baseline. The percentages of patients who have discontinued supplemental oxygen as of day 14 and day 28 are estimated from the Kaplan-Meier curve. |
| Time Frame | 28 days |
Outcome Measure Data
| Analysis Population Description |
|---|
| A subset of 204 patients from the modified intention-to-treat (mITT) population who required at least supplemental oxygen at baseline. 138 patients in the tocilizumab group and 66 patients in the placebo group required at least supplemental oxygen at baseline. |
| Arm/Group Title | Tocilizumab | Placebo |
|---|---|---|
| Arm/Group Description | Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg) | Standard care plus placebo |
| Measure Participants | 138 | 66 |
| Day 14 |
75.4
|
78.8
|
| Day 28 |
82.6
|
84.9
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Tocilizumab, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.69 |
| Comments | ||
| Method | Log Rank | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
| Estimated Value | 0.94 | |
| Confidence Interval |
(2-Sided) 95% 0.67 to 1.30 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Duration of Supplemental Oxygen |
|---|---|
| Description | Time from initiation of supplemental oxygen to end of supplemental oxygen use during 28-day study follow-up period. We includes all subjects in the analysis by assigning all subjects who did not receive supplemental oxygen a value of 0. Subjects who died prior to discontinuation of supplemental oxygen were given a value of the number of days from when supplemental oxygen began until the end of the follow-up period. |
| Time Frame | 28 days |
Outcome Measure Data
| Analysis Population Description |
|---|
| Modified intention-to-treat (mITT) population, which includes 242 patients (161 in the tocilizumab group and 81 in the placebo group) who underwent randomization and received either tocilizumab or placebo before intubation or death |
| Arm/Group Title | Tocilizumab | Placebo |
|---|---|---|
| Arm/Group Description | Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg) | Standard care plus placebo |
| Measure Participants | 161 | 81 |
| Median (Inter-Quartile Range) [days] |
4.0
|
3.9
|
| Title | Duration of Mechanical Ventilation |
|---|---|
| Description | Time from initiation of mechanical ventilation to end of mechanical ventilation during 28-day study follow-up period, among patients who received mechanical ventilation. Event times of patients who died without discontinuation of mechanical ventilation were censored at 28 days. Median and inter-quartile range (IQR) were estimated using Kaplan-Meier curves. The upper limit for the IQR was not reached for both arms and entered as 28 in the outcome measure data table. |
| Time Frame | 28 days |
Outcome Measure Data
| Analysis Population Description |
|---|
| A subset of 19 patients from the modified intention-to-treat (mITT) population who received mechanical ventilation during the study follow-up period. 11 patients in the tocilizumab group and 8 patients in the placebo group received mechanical ventilation. |
| Arm/Group Title | Tocilizumab | Placebo |
|---|---|---|
| Arm/Group Description | Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg) | Standard care plus placebo |
| Measure Participants | 11 | 8 |
| Median (Inter-Quartile Range) [days] |
15.0
|
27.9
|
| Title | Mortality |
|---|---|
| Description | Time from administration of the investigational agent (or placebo) to death. The percentage of patients who have died as of day 14 and day 28 are estimated from the Kaplan-Meier curve. |
| Time Frame | 28 days |
Outcome Measure Data
| Analysis Population Description |
|---|
| Modified intention-to-treat (mITT) population, which includes 242 patients (161 in the tocilizumab group and 81 in the placebo group) who underwent randomization and received either tocilizumab or placebo before intubation or death |
| Arm/Group Title | Tocilizumab | Placebo |
|---|---|---|
| Arm/Group Description | Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg) | Standard care plus placebo |
| Measure Participants | 161 | 81 |
| Day 14 |
4.4
|
1.3
|
| Day 28 |
5.6
|
3.8
|
| Title | ICU Admission or Death Among Those Not in the ICU at the Time of Administration of Investigational Agent (or Placebo) |
|---|---|
| Description | The percentage of subjects requiring ICU admission between baseline and 28 days is calculated by dividing the number of subjects requiring ICU admission over their hospitalization by the number of evaluable subjects (i.e., the number of subjects not in the ICU at the time of investigational treatment administration). |
| Time Frame | 28 days |
Outcome Measure Data
| Analysis Population Description |
|---|
| A subset of 233 patients from the modified intention-to-treat (mITT) population who were not in the ICU at baseline. 157 patients in the tocilizumab group and 76 patients in the placebo group were not in the ICU at baseline. |
| Arm/Group Title | Tocilizumab | Placebo |
|---|---|---|
| Arm/Group Description | Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg) | Standard care plus placebo |
| Measure Participants | 157 | 76 |
| Number [percentage of patients with event] |
15.9
|
15.8
|
| Title | Hospital Discharge |
|---|---|
| Description | Time from administration of the investigational medication (or placebo) to initial hospital discharge. Event times for patient who die are censored at day 29 to indicate that they never left the hospital during the follow-up period. The percentages of patients who were discharged as of day 14 and day 28 are estimated from the Kaplan-Meier curve. |
| Time Frame | 28 days |
Outcome Measure Data
| Analysis Population Description |
|---|
| Modified intention-to-treat (mITT) population, which includes 242 patients (161 in the tocilizumab group and 81 in the placebo group) who underwent randomization and received either tocilizumab or placebo before intubation or death |
| Arm/Group Title | Tocilizumab | Placebo |
|---|---|---|
| Arm/Group Description | Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg) | Standard care plus placebo |
| Measure Participants | 161 | 81 |
| Day 14 |
86.3
|
81.5
|
| Day 28 |
91.3
|
88.9
|
| Title | Clinical Improvement on Ordinal Scale |
|---|---|
| Description | Time to first improvement from administration of the investigational agent (or placebo) of at least 2 points (or the maximum amount) on the ordinal scale. Event times for patients who died prior to reaching this endpoint are censored at 29 days. Ordinal Scale Discharged Non-ICU hospital ward not requiring supplemental oxygen Non-ICU hospital ward requiring supplemental oxygen ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen ICU, requiring intubation and mechanical ventilation ICU, requiring ECMO or mechanical ventilation and additional organ support Death |
| Time Frame | 28 days |
Outcome Measure Data
| Analysis Population Description |
|---|
| Modified intention-to-treat (mITT) population, which includes 242 patients (161 in the tocilizumab group and 81 in the placebo group) who underwent randomization and received either tocilizumab or placebo before intubation or death |
| Arm/Group Title | Tocilizumab | Placebo |
|---|---|---|
| Arm/Group Description | Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg) | Standard care plus placebo |
| Measure Participants | 161 | 81 |
| Day 14 |
86.3
|
81.5
|
| Day 28 |
91.3
|
88.9
|
Adverse Events
| Time Frame | 0-28 days. An AE is any unfavorable and unintended sign (including an abnormal laboratory finding),symptom, or disease temporally associated with the use of an investigational medicinal product (IMP) or other protocol-imposed intervention, regardless of attribution. | |||
|---|---|---|---|---|
| Adverse Event Reporting Description | An SAE death It is life threatening It requires or prolongs inpatient hospitalization. It results in persistent or significant disability/incapacity It results in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the IMP. It is considered a significant medical event by the investigator based on medical judgment (e.g., may jeopardize the subject or may require medical/surgical intervention to prevent one of the outcomes listed above). | |||
| Arm/Group Title | Tocilizumab | Placebo | ||
| Arm/Group Description | Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg) | Standard care plus placebo | ||
All Cause Mortality |
||||
| Tocilizumab | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 9/161 (5.6%) | 4/82 (4.9%) | ||
Serious Adverse Events |
||||
| Tocilizumab | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 19/161 (11.8%) | 8/82 (9.8%) | ||
| Blood and lymphatic system disorders | ||||
| Neutrophil count decreased | 2/161 (1.2%) | 2 | 0/82 (0%) | 0 |
| Febrile Neutropenia | 1/161 (0.6%) | 1 | 0/82 (0%) | 0 |
| Elevated Partial Thromboplastin Time | 1/161 (0.6%) | 1 | 1/82 (1.2%) | 1 |
| Anemia | 0/161 (0%) | 0 | 1/82 (1.2%) | 1 |
| Bleeding | 0/161 (0%) | 0 | 1/82 (1.2%) | 1 |
| Cardiac disorders | ||||
| Arterial ischemia | 1/161 (0.6%) | 1 | 0/82 (0%) | 0 |
| Myocardial infarction | 0/161 (0%) | 0 | 1/82 (1.2%) | 1 |
| Cardiogenic Shock | 1/161 (0.6%) | 1 | 0/82 (0%) | 0 |
| Bradycardia | 0/161 (0%) | 0 | 1/82 (1.2%) | 1 |
| Hypertension | 0/161 (0%) | 0 | 1/82 (1.2%) | 1 |
| Hospitalization for Syncope | 0/161 (0%) | 0 | 1/82 (1.2%) | 1 |
| Gastrointestinal disorders | ||||
| Continued anorexia | 1/161 (0.6%) | 1 | 0/82 (0%) | 0 |
| Hepatobiliary disorders | ||||
| Elevated liver function test: Alanine aminotransferase | 1/161 (0.6%) | 1 | 1/82 (1.2%) | 1 |
| Elevated liver function test: Aspartate transaminase | 1/161 (0.6%) | 1 | 1/82 (1.2%) | 1 |
| Infections and infestations | ||||
| Infection | 4/161 (2.5%) | 4 | 6/82 (7.3%) | 6 |
| Musculoskeletal and connective tissue disorders | ||||
| Hip fracture requiring hospitalization | 1/161 (0.6%) | 1 | 0/82 (0%) | 0 |
| Nervous system disorders | ||||
| Seizure | 0/161 (0%) | 0 | 1/82 (1.2%) | 1 |
| Stroke | 2/161 (1.2%) | 2 | 0/82 (0%) | 0 |
| Parasthesia | 0/161 (0%) | 0 | 1/82 (1.2%) | 1 |
| Renal and urinary disorders | ||||
| Low output from nephrostomy tube | 1/161 (0.6%) | 1 | 0/82 (0%) | 0 |
| Patient re-hospitalized because dialysis could not be arranged any other way | 1/161 (0.6%) | 1 | 0/82 (0%) | 0 |
| Renal injury | 0/161 (0%) | 0 | 1/82 (1.2%) | 1 |
| Respiratory, thoracic and mediastinal disorders | ||||
| Hypoxia | 2/161 (1.2%) | 2 | 2/82 (2.4%) | 3 |
| Pulmonary Fibrosis | 1/161 (0.6%) | 1 | 0/82 (0%) | 0 |
| Tracheostomy | 0/161 (0%) | 0 | 1/82 (1.2%) | 1 |
| Tachypnea | 0/161 (0%) | 0 | 1/82 (1.2%) | 1 |
| Dysphagia | 0/161 (0%) | 0 | 1/82 (1.2%) | 1 |
| respiratory failure and intubation | 0/161 (0%) | 0 | 1/82 (1.2%) | 1 |
| Respiratory Acidosis | 0/161 (0%) | 0 | 1/82 (1.2%) | 1 |
| Skin and subcutaneous tissue disorders | ||||
| Hypothermia | 0/161 (0%) | 0 | 1/82 (1.2%) | 1 |
| Grade 3: Rash/allergic reaction | 0/161 (0%) | 0 | 1/82 (1.2%) | 1 |
| Vascular disorders | ||||
| Deep venous thrombosis | 2/161 (1.2%) | 2 | 2/82 (2.4%) | 2 |
| Pulmonary embolism | 1/161 (0.6%) | 1 | 2/82 (2.4%) | 2 |
| Hypotension | 3/161 (1.9%) | 3 | 2/82 (2.4%) | 2 |
Other (Not Including Serious) Adverse Events |
||||
| Tocilizumab | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 20/161 (12.4%) | 26/81 (32.1%) | ||
| Blood and lymphatic system disorders | ||||
| Anemia | 1/161 (0.6%) | 1 | 2/81 (2.5%) | 2 |
| decreased white blood cell count | 3/161 (1.9%) | 3 | 1/81 (1.2%) | 1 |
| Hypotension | 2/161 (1.2%) | 2 | 3/81 (3.7%) | 3 |
| decreased hemoglobin | 0/161 (0%) | 0 | 1/81 (1.2%) | 1 |
| hypomagnesemia | 0/161 (0%) | 0 | 1/81 (1.2%) | 1 |
| Mild edema | 0/161 (0%) | 0 | 2/81 (2.5%) | 2 |
| Cardiac disorders | ||||
| Bradycardia | 1/161 (0.6%) | 1 | 0/81 (0%) | 0 |
| Hypertension | 2/161 (1.2%) | 2 | 2/81 (2.5%) | 2 |
| Paroxysmal Atrial fibrillation | 1/161 (0.6%) | 1 | 1/81 (1.2%) | 1 |
| Ear and labyrinth disorders | ||||
| Ear ache | 1/161 (0.6%) | 1 | 0/81 (0%) | 0 |
| Eye disorders | ||||
| Conjunctivitis | 1/161 (0.6%) | 1 | 0/81 (0%) | 0 |
| Gastrointestinal disorders | ||||
| Diarrhea | 2/161 (1.2%) | 2 | 1/81 (1.2%) | 1 |
| Constipation | 0/161 (0%) | 0 | 1/81 (1.2%) | 1 |
| Vomitting | 0/161 (0%) | 0 | 1/81 (1.2%) | 1 |
| Immune system disorders | ||||
| Decreased poly(ADP-ribosyl)ation | 1/161 (0.6%) | 1 | 0/81 (0%) | 0 |
| Injury, poisoning and procedural complications | ||||
| worsening lower extremity wound | 1/161 (0.6%) | 1 | 0/81 (0%) | 0 |
| FALL WITH ABRASION | 0/161 (0%) | 0 | 2/81 (2.5%) | 2 |
| Nervous system disorders | ||||
| Worsening confusion | 1/161 (0.6%) | 1 | 1/81 (1.2%) | 1 |
| Dizziness | 0/161 (0%) | 0 | 1/81 (1.2%) | 1 |
| Headache | 0/161 (0%) | 0 | 1/81 (1.2%) | 1 |
| Renal and urinary disorders | ||||
| Acute kidney injury | 1/161 (0.6%) | 1 | 0/81 (0%) | 0 |
| Increased alkaline phosphatase | 1/161 (0.6%) | 1 | 1/81 (1.2%) | 1 |
| acute kidney injury with AGMA and hyperkalemia | 0/161 (0%) | 0 | 1/81 (1.2%) | 1 |
| Respiratory, thoracic and mediastinal disorders | ||||
| Mucus plugging | 0/161 (0%) | 0 | 1/81 (1.2%) | 1 |
| Oropharyngeal Dysphagia | 0/161 (0%) | 0 | 1/81 (1.2%) | 1 |
| Skin and subcutaneous tissue disorders | ||||
| Pruritic Rash | 1/161 (0.6%) | 1 | 0/81 (0%) | 0 |
| Vascular disorders | ||||
| Acute superficial thrombophlebitis | 0/161 (0%) | 0 | 1/81 (1.2%) | 1 |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | DRAI Director of Clinical Trials |
|---|---|
| Organization | Massachusetts General Hospital |
| Phone | 617-726-7938 |
| JHSTONE@mgh.harvard.edu |
- 2020P001159